Novartis stock holds firm as investors await fresh data
Published on 08/22/2026 at 07:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock closed around $163.78 in a recent valuation snapshot, alongside a market capitalization of $227.35 billion and a 3.03 percent dividend yield. The company behind the NVS ticker also reported $56.7 billion in revenue in its latest profile view, giving investors a current scale reference as they assess the next step.
Revenue stays large
The revenue figure of $56.7 billion is the most useful operating anchor in the available material, and it sits far above the smaller regional listings tied to other Novartis names. That gap matters because it separates the global drug group from local market references that can otherwise blur the picture.
A second figure stands out in the same snapshot: income of $12.76 billion. With that level of profitability, Novartis remains a cash-generating large-cap health care name rather than a story driven only by pipeline optionality.
What the market sees
The latest market view also includes an AI price target of $163.78, with a high forecast of $173.60 and a low forecast of $144.15. That range frames the stock at a modest premium to the quoted level in the same source, which suggests the market is still balancing earnings power against valuation.
For a cross-check, the same snapshot shows a 21.95 P/E and a 17.05 price-to-free-cash-flow ratio. Those ratios are not stretched for a global drug maker with $54.79 billion in sales and a 29.93 percent return on equity, but they also leave less room for disappointment.
Product scale
Novartis' drug portfolio spans oncology, immunology and cardiovascular medicine, with blockbuster products such as Cosentyx and Entresto carrying much of the commercial weight. That mix helps explain why the company's revenue base remains broad even when one product cycle slows.
More on Novartis stock: the company is still priced like a mature defensive name, not a turnaround trade.
Price and valuation
As of August 21, 2026, the most recent quote in the available material shows Novartis trading at $156.27, while the same source places the current market cap at $227.35 billion. That keeps the stock within the upper half of the current valuation band and gives the market a clear test if earnings momentum holds.
More on Novartis stock
Company: Novartis AG
ISIN: CH0012005267
Ticker: NVS
Exchange: NYSE
Price (as of August 21, 2026, 4:00 p.m. ET): $156.27 USD
Market cap: $227.35 billion (as of August 21, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: S&P 500
